Immunocore Holdings plc (NASDAQ:IMCR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Immunocore Holdings plc (NASDAQ:IMCR) has earned an average recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $69.18.

Several research firms have recently issued reports on IMCR. Oppenheimer reaffirmed an “outperform” rating and set a $89.00 target price (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research note on Thursday, October 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. UBS Group started coverage on shares of Immunocore in a research note on Thursday, October 24th. They issued a “sell” rating and a $24.00 price target for the company. Finally, Guggenheim cut shares of Immunocore from a “buy” rating to a “neutral” rating in a research note on Monday, October 7th.

Immunocore Stock Down 3.2 %

Immunocore stock opened at $31.59 on Friday. Immunocore has a fifty-two week low of $29.72 and a fifty-two week high of $76.98. The stock has a market cap of $1.58 billion, a PE ratio of -33.25 and a beta of 0.72. The firm’s 50-day simple moving average is $32.44 and its 200 day simple moving average is $38.66. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm had revenue of $80.25 million for the quarter, compared to analysts’ expectations of $78.94 million. During the same period in the previous year, the company earned ($0.59) earnings per share. The company’s quarterly revenue was up 23.7% on a year-over-year basis. Research analysts predict that Immunocore will post -0.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in IMCR. Primecap Management Co. CA increased its stake in shares of Immunocore by 3,841.6% in the 2nd quarter. Primecap Management Co. CA now owns 1,951,070 shares of the company’s stock worth $66,122,000 after acquiring an additional 1,901,570 shares in the last quarter. Armistice Capital LLC increased its stake in shares of Immunocore by 495.1% in the 2nd quarter. Armistice Capital LLC now owns 976,000 shares of the company’s stock worth $33,077,000 after acquiring an additional 812,000 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock worth $219,430,000 after acquiring an additional 668,382 shares in the last quarter. Millennium Management LLC increased its stake in shares of Immunocore by 124.4% in the 2nd quarter. Millennium Management LLC now owns 600,954 shares of the company’s stock worth $20,366,000 after acquiring an additional 333,167 shares in the last quarter. Finally, Two Sigma Advisers LP increased its stake in shares of Immunocore by 65.6% in the 3rd quarter. Two Sigma Advisers LP now owns 757,700 shares of the company’s stock worth $23,587,000 after acquiring an additional 300,200 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.